Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
Beyond Nanosizing: Mechanism-Guided Design and Rational Selection of Polymeric and Lipid Nanocarriers for Translatable Drug Delivery.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Singh Bishal, Sah Abhisekh, Gautam Rajesh, Thakur Gaurav, Kumar Deepak, Jayaswal Jigyasa, Kumar Shivam
Аннотация
BACKGROUND: Nanosizing can modify dissolution and carrier behaviour, but particle size alone does not determine clinically useful exposure.
OBJECTIVE: To compare polymeric and lipid-based nanocarriers using a mechanism-guided framework that links payload properties, composition, process conditions, biological barriers, critical quality attributes (CQAs), and translational risk.
METHODS: A critical narrative review with a structured scoping update was performed using PubMed, Scopus, Web of Science, and Google Scholar during manuscript preparation. The intended publication window was 2010-2025, with earlier seminal studies retained where mechanistically necessary. Because exact search dates, an auditable database export, screening counts, and independent-reviewer records were not preserved, this review is not presented as a systematic review and no pooled effect estimate is reported.
RESULTS: Polymeric systems can stabilize selected amorphous or molecularly dispersed payloads and tune release through diffusion, hydration, and degradation, whereas lipid systems can support lipid-phase solubilization, digestion-dependent oral absorption, membrane interaction, and nucleic-acid delivery. Across both classes, precipitation, release failure, phase transformation, protein-corona and immune effects, endosomal sequestration, and process drift can disconnect favorable in vitro attributes from human pharmacology. Clinical examples show product-specific changes in disposition, safety, or efficacy rather than a universal bioavailability multiplier.
CONCLUSION: Rational nanocarrier selection should start from a testable mechanism and a defined translational risk, then be challenged with route-relevant biological assays, exposure measurements, safety data, and manufacturing comparability. The proposed framework is hypothesis-generating and requires prospective validation.
OBJECTIVE: To compare polymeric and lipid-based nanocarriers using a mechanism-guided framework that links payload properties, composition, process conditions, biological barriers, critical quality attributes (CQAs), and translational risk.
METHODS: A critical narrative review with a structured scoping update was performed using PubMed, Scopus, Web of Science, and Google Scholar during manuscript preparation. The intended publication window was 2010-2025, with earlier seminal studies retained where mechanistically necessary. Because exact search dates, an auditable database export, screening counts, and independent-reviewer records were not preserved, this review is not presented as a systematic review and no pooled effect estimate is reported.
RESULTS: Polymeric systems can stabilize selected amorphous or molecularly dispersed payloads and tune release through diffusion, hydration, and degradation, whereas lipid systems can support lipid-phase solubilization, digestion-dependent oral absorption, membrane interaction, and nucleic-acid delivery. Across both classes, precipitation, release failure, phase transformation, protein-corona and immune effects, endosomal sequestration, and process drift can disconnect favorable in vitro attributes from human pharmacology. Clinical examples show product-specific changes in disposition, safety, or efficacy rather than a universal bioavailability multiplier.
CONCLUSION: Rational nanocarrier selection should start from a testable mechanism and a defined translational risk, then be challenged with route-relevant biological assays, exposure measurements, safety data, and manufacturing comparability. The proposed framework is hypothesis-generating and requires prospective validation.